



IFW

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

SUNDREHAGEN et al.

Serial No.: 10/539,797

Filed: December 19, 2005

For: CVD ASSAY

Attention:

PCT Legal Office

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Supplemental Information Disclosure Statement is being submitted with thirteen additional references cited in prosecution and, more recently, during opposition of a case relating to a similar subject matter that Axis-Shield ASA is opposing.

This Information Disclosure Statement along with references is submitted prior to the mailing date of the first Official Action on the merits received by Applicants in the above-identified application.

The Examiner is requested to acknowledge consideration of the information provided in this paper in accordance with prescribed procedures.


Respectfully submitted,  
BACON & THOMAS, PLLC

By: Richard E. Fichter  
Richard E. Fichter  
Registration No. 26,382

625 Slaters Lane, 4<sup>th</sup> Fl.  
Alexandria, Virginia 22314  
Phone: (703) 683-0500  
Facsimile: (703) 683-1080

REF:cjw  
Supplemental IDS.wpd

October 24, 2006



B/O Form PTO-1449  U.S. Department of Commerce Patent and Trademark Office  Information Disclosure Statement by Applicant	Atty. Docket Number	Serial Number
	COCK3001/REF	10/539,797
	Applicant	
	Erling SUNDREHAGEN	
	Filing Date	Group
	December 19, 2005	1641

## U.S. Patent Documents

Examiner Initial	Document Number	Date	Patentee/Applicant	Class	Subclasses	Filing Date if Appropriate
	4,287,202	09/01/1981	David F. Horrobin			

## Foreign Patent Documents

Examiner Initial	Document Number	Publication Date	Country/Agency	Class	Subclass	Translation	
						Yes	No
	0 194 686 A1	09/17/1986	EP				
	60 139621 A	07/24/1985	JP (Abstract Only)			X	

## Other Documents (Including Author, Title, Date, Pertinent Pages, Place of Publication, Etc.)

	F. Haverkate, et al., "C-reactive protein and cardiovascular disease", Fibrinolysis and Proteolysis, 1997, vol. 11, no. 1, pp. 133-134
	G. Di Minno, "Piastrine, Prostaglandine E Trombosi", Giorn. Arterioscler., vol. 3, no. 2, 1978, Database BIOSIS, AN 79:244445, pp. 101-109
	Lewis H. Kuller, et al., "Relation of C-Reactive Protein and Coronary Heart Disease in the MRFIT Nested Case-Control Study", American Journal of Epidemiology, 1996, vol. 144, no. 6, pp. 537-547
	Frits Haverkate, et al., "Production of C-reactive protein and risk of coronary events in stable and unstable angina", The Lancet, February 15, 1997, vol. 349, pp. 462-466
	Shih-Jen Hwang, PhD., et al., "Circulating Adhesion Molecules VCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary Heart Disease Cases - The Atherosclerosis Risk In Communities (ARIC) Study", Circulation, December 16, 1997, vol. 96, no. 12, pp. 4219-4225
	Simon G. Thompson, et al., "Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris", The New England Journal of Medicine, March 9, 1995, vol. 332, no. 10, pp. 635-641
	Paul M. Ridker, M.D., et al., "Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men", The New England Journal of Medicine, April 3, 1997, vol. 336, no. 14, pp. 973-979
	JoAnn E. Manson, MD, et al., "A Prospective Study of Aspirin Use and Primary Prevention of Cardiovascular Disease in Women", JAMA, July 24-31, 1991, vol. 266, no. 4, pp. 521-527
	Multiple Risk Factor Intervention Trial Research Group, "Multiple Risk Factor Intervention Trial - Risk Factor Changes and Mortality Results", JAMA, September 24, 1982, vol. 248, no. 12, pp. 1465-1477
	Steering Committee of the Physicians' Health Study Research Group, "Final Report on the Aspirin Component of the Ongoing Physicians' Health Study", The New England Journal of Medicine, July 20, 1989, vol. 321, no. 3, pp. 129-135

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.